The Food and Drug Administration (FDA) is pushing for greater authority over hemp-derived cannabinoid products, signaling a possible shift in the cannabis industry's regulatory landscape. The move coincides with the upcoming Benzinga Cannabis Capital Conference, where top FDA officials will provide insights into the agency's position.
Norman Birenbaum, the FDA's Sr. Public Health Advisor, and Patrick Cournoyer, Lead for Cannabis Products, will share the stage at the Benzinga Cannabis Capital Conference, addressing the potential benefits of this call for heightened oversight. Their engagement in this influential gathering will underscore the seriousness of the matter and its potential ramifications for manufacturers, regulatory bodies and the end consumers.
The Benzinga Cannabis Capital Conference
Jason Raznick, CEO of Benzinga, underscores the magnitude of the event, stating, ...